Epizyme price target raised to $52 from $37 at Wedbush Wedbush increased its price target on Epizyme after the company released clinical data on its EPZ-5676 treatment that the firm views as positive. The firm reiterates an Outperform rating on the stock.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Epizyme sees ending 2014 with about $170M in cash and equivalents The company said, "With the successful completion of our follow-on offering in February 2014, which raised $101 million in net proceeds, we expect to end 2014 with approximately $170M in cash and cash equivalents, which we expect will fund the Company through at least mid-2016 prior to including any potential future milestone payments."